CPAP (continuous positive airway pressure) is the most commonly prescribed treatment. Oral appliance therapy (mandibular advancement devices) is an alternative for mild to moderate OSA or CPAP-intolerant patients. Surgical options include uvulopalatopharyngoplasty, maxillomandibular advancement, and hypoglossal nerve stimulation. Weight management, positional therapy, and myofunctional therapy serve as adjunctive treatments. The choice depends on severity, anatomy, and patient preference.

Oral appliances reduce the AHI by 50 percent or more in approximately 65 to 75 percent of patients with mild to moderate OSA. Complete normalization of the AHI (below 5 events per hour) occurs in approximately 35 to 50 percent of cases. Overall health outcomes — blood pressure reduction, daytime alertness improvement, and cardiovascular risk reduction — are comparable to CPAP because of higher nightly compliance rates.

Yes. The American Academy of Sleep Medicine specifically recommends oral appliance therapy for patients who are intolerant of CPAP. Oral appliances are silent, portable, require no electricity, and are significantly better tolerated — compliance rates exceed 80 percent compared to approximately 50 percent for CPAP. For many patients, switching to an oral appliance transforms their sleep treatment from a burden into a non-issue.

After the consultation and impressions or digital scanning, the custom appliance is fabricated in approximately two to three weeks. A fitting appointment ensures proper fit and function. Titration begins immediately — the mandibular position is gradually advanced over several weeks until best airway improvement is achieved. Follow-up sleep testing verifies efficacy.

Minor bite changes (slight shift in how back teeth contact) can occur with long-term mandibular advancement device use. Morning jaw exercises prescribed by the clinical team help minimize these shifts. Significant occlusal changes are uncommon with modern titratable devices at appropriate protrusion levels. Bite stability is monitored at every follow-up appointment.

Absolutely — and this is a major advantage over CPAP. An oral appliance fits in a pocket-sized case, requires no electricity, makes no noise, and clears security screening without explanation. It is the ideal sleep apnea treatment for frequent travelers, camping, and any situation where CPAP logistics are impractical.

The Apnea-Hypopnea Index measures the number of apnea and hypopnea events per hour of sleep. Normal is below 5. Mild OSA: 5 to 15. Moderate: 15 to 30. Severe: above 30. Treatment aims to reduce the AHI below 5, or at least below 10 with a 50 percent reduction from baseline. Follow-up sleep testing after treatment initiation documents the achieved AHI reduction.

After initial titration (weekly to biweekly adjustments over four to eight weeks), follow-up sleep testing documents treatment efficacy. Annual follow-up appointments assess appliance condition, bite stability, TMJ health, and subjective symptom status. Repeat sleep testing may be indicated if symptoms recur or the appliance requires adjustment.

Most medical insurance plans cover oral appliance therapy for diagnosed OSA, typically with documentation of CPAP intolerance for severe cases. The ADSC administrative team handles medical insurance pre-authorization, submits the necessary clinical documentation (sleep study results, clinical notes), and works to maximize coverage before treatment begins.

Genetic factors contribute significantly to OSA risk. Craniofacial structure (jaw size, airway dimensions), body fat distribution, and neuromuscular control of the pharynx all have hereditary components. If a parent or sibling has sleep apnea, your risk is improved. This genetic predisposition is one reason airway assessment is included in pediatric dental evaluations at ADSC — identifying structural risk factors early in development.

For patients whose apnea is significantly worse in the supine (back-sleeping) position — called positional OSA — avoiding back sleep can reduce AHI substantially. Positional therapy devices (vests, belts, or electronic position monitors) discourage supine sleep. Positional therapy may be sufficient for mild positional OSA or serve as an adjunct to oral appliance therapy.

OSA is a chronic condition — it does not resolve spontaneously (except in cases where significant weight loss or surgical correction eliminates the anatomical cause). Treatment is ongoing. The positive outlook is that consistent use of CPAP or oral appliance therapy effectively controls the condition, reducing cardiovascular risk, improving cognitive function, and restoring quality of life.

Yes. The repetitive sympathetic nervous system surges triggered by each apnea event during sleep cause sustained hypertension. OSA is an independent risk factor for resistant hypertension (high blood pressure that does not respond adequately to medication). Treatment of OSA with CPAP or oral appliance therapy produces measurable blood pressure reduction, particularly in patients who use their treatment device consistently every night.

Subjective improvement — less snoring, less daytime sleepiness, fewer morning headaches, partner reports of quieter sleep — provides initial feedback. However, objective verification requires a follow-up sleep study (home sleep test or polysomnography) performed while wearing the appliance. This documents the actual AHI reduction and confirms that the appliance is adequately treating the apnea.

The clinician verifies that the appliance seats properly on the upper and lower teeth, checks for any pressure points, adjusts the retention mechanism, sets the initial mandibular advancement position (typically 50 percent of maximum protrusion), and demonstrates the titration mechanism. You receive instructions on nightly use, cleaning, storage, and the advancement schedule for the titration phase.